SPX3,933.92-7.34 -0.19%
DIA336.44-0.02 -0.01%
IXIC10,958.55-56.34 -0.51%

Chardan Capital Downgrades Evelo Biosciences to Neutral, Announces $2.5 Price Target

Benzinga · 11/16/2022 08:27
Chardan Capital analyst Keay Nakae downgrades Evelo Biosciences (NASDAQ:EVLO) from Buy to Neutral and announces $2.5 price target.